{"id":"NCT01370642","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Na誰ve Chronic Hepatitis C Participants (MK-7009-043)","officialTitle":"A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Na誰ve Patients With Chronic Hepatitis C Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06-27","primaryCompletion":"2013-07-31","completion":"2014-03-17","firstPosted":"2011-06-10","resultsPosted":"2014-10-06","lastUpdate":"2018-10-18"},"enrollment":294,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"vaniprevir","otherNames":["MK-7009"]},{"type":"DRUG","name":"Placebo to vaniprevir","otherNames":[]},{"type":"BIOLOGICAL","name":"Peg-IFN","otherNames":["PegIntron"]},{"type":"DRUG","name":"ribavirin","otherNames":["REBETOL速"]}],"arms":[{"label":"Vaniprevir 12 Week Arm","type":"EXPERIMENTAL"},{"label":"Vaniprevir 24 Week Arm","type":"EXPERIMENTAL"},{"label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety, tolerability, and efficacy of vaniprevir given in combination with pegylated interferon alfa-2b (peg-IFN) and ribavirin (RBV) versus treatment with peg-IFN and RBV alone in Japanese treatment-na誰ve participants with chronic hepatitis C (CHC) genotype (GT)1. The primary efficacy hypothesis is that the percentage of participants achieving sustained virologic response 24 weeks after completion of all study therapy (SVR24) in at least one of the vaniprevir arms is superior to the percentage of participants achieving SVR24 in the control arm.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)","timeFrame":"24 weeks after 24 or 48 weeks of study therapy (up to 72 weeks)","effectByArm":[{"arm":"Vaniprevir 12 Week Arm","deltaMin":83.7,"sd":null},{"arm":"Vaniprevir 24 Week Arm","deltaMin":84.5,"sd":null},{"arm":"Control Arm","deltaMin":55.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26403160","26947564"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":98},"commonTop":["Pyrexia","Headache","Neutrophil count decreased","White blood cell count decreased","Rash"]}}